Tango Therapeutics, Inc.
TNGX
शेयरों में रैंक
#4540
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
शेयर मूल्य
$27.18
अंतिम समन्वयन: 2026-07-31
मार्केट कैप
$3.38B
बदलाव (1 दिन)
-1.41%
बदलाव (1 वर्ष)
197.05%
देश
US
व्यापार Tango Therapeutics, Inc. (TNGX)
श्रेणी
Healthcare
Tango Therapeutics, Inc. (TNGX) के लिए EPS
June 2026 TTM तक का EPS: $-0.85
Tango Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $-0.85 है। 2023 के अंत में, कंपनी का EPS $-1.08 था, जो 2022 के EPS $-1.23 के की तुलना में कमी था।
Tango Therapeutics, Inc. के लिए 2019 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
| वर्ष | EPS | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-0.85 | -28.57% |
| 2024 | $-1.19 | 10.19% |
| 2023 | $-1.08 | -12.20% |
| 2022 | $-1.23 | 30.85% |
| 2021 | $-0.94 | -41.98% |
| 2020 | $-1.62 | 3.18% |
| 2019 | $-1.57 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
| कंपनी | EPS | EPS अंतर | देश |
|---|---|---|---|
| $17.32 | -2,137.65% |
US
|
|
| $-7.98 | 838.82% |
US
|
|
| $-5.29 | 522.35% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,363.53% |
NL
|
